首页> 外文期刊>Diabetes >11β-Hydroxysteroid Dehydrogenase Type 1 Regulates Glucocorticoid-Induced Insulin Resistance in Skeletal Muscle
【24h】

11β-Hydroxysteroid Dehydrogenase Type 1 Regulates Glucocorticoid-Induced Insulin Resistance in Skeletal Muscle

机译:11β-羟基类固醇脱氢酶1型调节糖皮质激素诱导的骨骼肌胰岛素抵抗。

获取原文
获取原文并翻译 | 示例
       

摘要

Objective-Glucocorticoid excess is characterized by increased adiposity, skeletal myopathy, and insulin resistance, but the precise molecular mechanisms are unknown. Within skeletal muscle, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts cortisone (11-dehydrocorticosterone in rodents) to active cortisol (corticosterone in rodents). We aimed to determine the mechanisms underpinning glucocorticoid-induced insulin resistance in skeletal muscle and indentify how 11β-HSD1 inhibitors improve insulin sensitivity.rnResearch design and methods-Rodent and human cell cultures, whole-tissue explants, and animal models were used to determine the impact of glucocorticoids and selective 11β-HSD1 inhibition upon insulin signaling and action.rnResults-Dexamethasone decreased insulin-stimulated glucose uptake, decreased IRS1 mRNA and protein expression, and increased inactivating pSer~(307) insulin receptor substrate (IRS)-1. 11β-HSD1 activity and expression were observed in human and rodent myotubes and muscle explants. Activity was predominantly oxo-reductase, generating active glucocorticoid. Al (selective 11β-HSD1 inhibitor) abolished enzyme activity and blocked the increase in pSer~(307) IRS1 and reduction in total IRS1 protein after treatment with 11DHC but not corticosterone. In C57B16/J mice, the selective 11β-HSDl inhibitor, A2, decreased fasting blood glucose levels and improved insulin sensitivity. In KK mice treated with A2, skeletal muscle pSer~(307) IRS1 decreased and pThr~(308) Akt/PKB increased. In addition, A2 decreased both lipogenic and lipolytic gene expression.rnConclusions-Prereceptor facilitation of glucocorticoid action via lip-HSDl increases pSer~(307) IRS1 and may be crucial in mediating insulin resistance in skeletal muscle. Selective 11β-HSD1 inhibition decreases pSer~(307) IRS1, increases pThr~(308) Akt/ PKB, and decreases lipogenic and lipolytic gene expression that may represent an important mechanism underpinning their insulin-sensitizing action.
机译:客观糖皮质激素过量的特征是肥胖,骨骼肌病和胰岛素抵抗增加,但确切的分子机制尚不清楚。在骨骼肌中,1β-羟类固醇脱氢酶1(11β-HSD1)将可的松(啮齿动物中的11-脱氢皮质酮)转化为活性皮质醇(啮齿动物中的皮质酮)。我们旨在确定支撑糖皮质激素诱导的骨骼肌胰岛素抵抗的机制,并确定11β-HSD1抑制剂如何提高胰岛素敏感性。研究设计和方法-啮齿动物和人类细胞培养,全组织外植体和动物模型用于确定胰岛素抵抗结果:地塞米松降低了胰岛素刺激的葡萄糖摄取,降低了IRS1 mRNA和蛋白表达,并增加了失活的pSer〜(307)胰岛素受体底物(IRS)-1。在人和啮齿动物的肌管和肌肉外植体中观察到11β-HSD1活性和表达。活性主要是氧化还原酶,产生活性糖皮质激素。 Al(选择性11β-HSD1抑制剂)取消了酶活性,并阻止了11DHC但未使用皮质酮治疗后pSer〜(307)IRS1的增加和总IRS1蛋白的减少。在C57B16 / J小鼠中,选择性11β-HSD1抑制剂A2降低了空腹血糖水平并改善了胰岛素敏感性。在用A2处理的KK小鼠中,骨骼肌pSer〜(307)IRS1减少,而pThr〜(308)Akt / PKB增加。此外,A2降低了脂肪形成和脂解性基因的表达。结论:通过唇-HSD1促进糖皮质激素作用的受体促进了pSer〜(307)IRS1的表达,在介导骨骼肌胰岛素抵抗中可能至关重要。选择性的11β-HSD1抑制作用会降低pSer〜(307)IRS1,增加pThr〜(308)Akt / PKB,并降低脂原性和脂解性基因表达,这可能是其胰岛素敏化作用的重要机制。

著录项

  • 来源
    《Diabetes》 |2009年第11期|2506-2515|共10页
  • 作者单位

    Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;

    Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;

    Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;

    Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;

    AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;

    Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;

    AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;

    AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;

    AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;

    AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;

    Department of Clinical Biochemistry, University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.;

    Department of Clinical Biochemistry, University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.;

    Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;

    AstraZeneca Diabetes & Obesity Drug Discovery, Mereside, Alderley Park, Macclesfield, Cheshire, U.K.;

    Centre for Endocrinology, Diabetes and Metabolism, Institute of Biomedical Research, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, U.K.;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:46:44

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号